Updated on 10 August 2012
Singapore: 3SBio, a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, has made changes in its board of directors. Mr Lawrence Wizel submitted his resignation from 3SBio's board of directors, effective September 1, 2012, due to health reasons.
He served as an independent director on the board since 2006 and was the chair of the audit committee and a member of the compensation committee and the investment committee at the time of resignation.
Effective September 1, 2012, Mr Tianruo (Robert) Pu will join 3SBio's board of directors as an independent director, with appointment to serve in the audit committee as the chair and in the compensation committee. Mr Pu currently chairs the audit committee of UTStarcom Holdings and also serves on its other board committees. From September 2008 to June 2012, Mr Pu was the chief financial officer of China Nuokang Bio-Pharmaceutical where he successfully led Nuokang Biopharma's IPO process and was responsible for its M&A and corporate growth strategy.
Dr Jing Lou, chief executive officer said, "On behalf of the board of directors, I would like to thank Larry for his many contributions to 3SBio over the past six years." He continued, "We are also pleased to welcome Robert Pu to the board as an independent director and look forward to his expertise, advice and counsel."